Laboratório de Virologia Molecular, Fundação Oswaldo Cruz, Fiocruz, Rondônia, Brazil.
COVID-19 Response - Internation Task Force, Centers for Diseases Control and Prevention (CDC), Atlanta, Georgia, USA.
J Med Virol. 2022 Jul;94(7):3410-3415. doi: 10.1002/jmv.27686. Epub 2022 Mar 22.
Through active surveillance and contact tracing from outpatients, we aimed to identify and characterize SARS-CoV-2 variants circulating in Porto Velho-Rondônia, a city in the Brazilian Amazon. As part of a prospective cohort, we gathered information from 2,506 individuals among COVID-19 patients and household contacts. Epidemiological data, nasopharyngeal swabs, and blood samples were collected from all participants. Nasopharyngeal swabs were tested for antigen rapid diagnostic test and reverse transcription-polymerase chain reaction (RT-PCR) followed by genomic sequencing. Blood samples underwent ELISA testing for IgA, IgG, and IgM antibody levels. From 757 specimens sequenced, three were identified as Mu variant, none of the individuals carrying this variant had a travel history in the previous 15 days before diagnosis. One case was asymptomatic and two presented mild symptoms. Two infected individuals from different households caring viruses with additional amino acid substitutions ORF7a P45L and ORF1a T1055A compared to the Mu virus reference sequence. One patient presented IgG levels. Our results highlight that genomic surveillance for SARS-CoV-2 variants can assist in detecting the emergency of SARS-CoV-2 variants in the community, before its identification in other parts of the country.
通过对门诊患者的主动监测和接触者追踪,我们旨在确定和描述在巴西亚马逊州波多韦柳市(Porto Velho-Rondônia)流行的 SARS-CoV-2 变体。作为前瞻性队列的一部分,我们从 COVID-19 患者和家庭接触者中收集了 2506 名个体的信息。对所有参与者采集了流行病学数据、鼻咽拭子和血液样本。对所有鼻咽拭子进行抗原快速诊断检测和逆转录-聚合酶链反应(RT-PCR)检测,并进行基因组测序。对血液样本进行酶联免疫吸附试验(ELISA)检测以检测 IgA、IgG 和 IgM 抗体水平。从测序的 757 个样本中,发现了 3 个 Mu 变体,这些个体均无在诊断前 15 天内的旅行史。一个病例无症状,两个表现为轻症。来自两个不同家庭的两个受感染个体携带与 Mu 病毒参考序列相比具有额外氨基酸取代的 ORF7a P45L 和 ORF1a T1055A。一个患者出现 IgG 水平升高。我们的研究结果强调,对 SARS-CoV-2 变体的基因组监测有助于在其在该国其他地区得到识别之前,检测社区中 SARS-CoV-2 变体的出现。